Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% versus 1.8% with Ozempic. Lilly said retatrutide also produced more than double the weight loss of Ozempic’s highest approved dose.
Eli Lilly (NYSE: LLY ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Full Transcript OPERATOR Ladies and gentlemen, thank you f
Eli Lilly's experimental combination drug EloraTZP led to an average body weight loss of 23.3% over 48 weeks in a mid-stage trial, compared to 14.8% for its blockbuster Zepbound alone. The company plans to start late-stage trials for EloraTZP in the fourth quarter of 2026.